Kyongbo Pharmaceutical Co., Ltd

A214390

KR7214390007

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 26/03/2024 GMT			5-day change	1st Jan Change
7,440 ^KRW	-2.75%		-.--%	-11.32%

2023	Pharosgen Co., Ltd. announced that it has received KRW 1.999997692 billion in funding from Kyongbo Pharmaceutical Co., Ltd	CI
2023	Kyongbo Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Chong Kun Dang Holdings Corp. agreed to acquire an additional 6.3% stake in Kyongbo Pharmaceutical Co., Ltd. for KRW 19.7 billion.

April 26, 2017

Chong Kun Dang Holdings Corp. (KOSE:A001630) agreed to acquire an additional 6.3% stake in Kyongbo Pharmaceutical Co., Ltd. (KOSE:A214390) for KRW 19.7 billion on April 27, 2017. Under the terms, the buyer will acquire 1.5 million shares, increasing its shareholding to 39.5% in Kyongbo Pharmaceutical Co., Ltd.

Latest news about Kyongbo Pharmaceutical Co., Ltd

Pharosgen Co., Ltd. announced that it has received KRW 1.999997692 billion in funding from Kyongbo Pharmaceutical Co., Ltd	24/05/23	CI
Kyongbo Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Pharosgen Co., Ltd. announced that it expects to receive KRW 1.999997692 billion in funding from Kyongbo Pharmaceutical Co., Ltd	08/05/23	CI
Kyongbo Pharmaceutical Co., Ltd(KOSE:A214390) dropped from S&P Global BMI Index	19/09/22	CI
Can-Fite BioPharma Ltd. Signs Distribution Agreement with Kyongbo Pharm Co., Ltd	01/08/19	CI
AFT Pharmaceuticals Limited Starts to License Maxigesic IV with Deal in South Korea	05/11/18	CI
Chong Kun Dang Holdings Corp. cancelled the acquisition of an additional 6.3% stake in Kyongbo Pharmaceutical Co., Ltd..	26/04/18	CI
Chong Kun Dang Holdings Corp. agreed to acquire an additional 6.3% stake in Kyongbo Pharmaceutical Co., Ltd. for KRW 19.7 billion.	26/04/17	CI
Kyongbo Pharmaceutical Co., Ltd.(KOSE:A214390) added to MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index	01/12/15	CI
Kyongbo Pharmaceutical Co., Ltd.(KOSE:A214390) added to Russell Global Index	01/10/15	CI
Kyongbo Pharmaceutical Co., Ltd.(KOSE:A214390) added to S&P Global BMI Index	21/09/15	CI
Kyongbo Pharmaceutical Co., Ltd. has completed an IPO in the amount of KRW 143.44 billion.	24/06/15	CI
Kyongbo Pharmaceutical Co. Ltd. has filed an IPO in the amount of KRW 143.45 billion.	15/05/15	CI

Chart Kyongbo Pharmaceutical Co., Ltd

Duration

Period

More charts

Company Profile

KYONGBO PHARMACEUTICAL CO., LTD is a Korea-based company principally engaged in manufacturing and distributing pharmaceutical products The Company operates its business through two segments: raw material medicine segment, which produces atorvastatin, ceftizoxime, ceftriaxone, clarithromycin and Pranlukast, and medicine segment, which produces surgeon respiratory solution, cefaclor capsule and cefaclor dry syrup. The Company distributes its products within domestic market and to overseas markets including China Japan and Europe.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KYONGBO PHARMACEUTICAL CO., LTD	-11.32%	130M
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.92%	364B
MERCK & CO., INC.	+20.36%	326B
ABBVIE INC.	+5.38%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+10.72%	167B
PFIZER, INC.	+0.16%	161B